This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

PHACE syndrome

Authoring team

PHACE syndrome (OMIM 606519)

  • posterior fossa and other structural brain malformations; large haemangiomas of the face, neck, and/or scalp; anomalies of cerebral or cervical
    arteries; cardiac anomalies/coarctation of the aorta; eye abnormalities and sternal clefting or supraumbilical raphe
  • acronym "PHACES" is sometimes used instead to include potential ventral midline defects, specifically sternal cleft and/or supraumbilical raphe (2)
  • crebrovascular anomalies, present in more than 90% of patients with PHACE syndrome, are the most common extracutaneous feature of the syndrome, followed by cardiac anomalies (67%) and structural brain anomalies (52%) (2)
  • risk of PHACE syndrome in an infant presenting with a large segmental infantile haemangioma (IH) of the head or neck is approximately 30% (2)

Over 300 cases of PHACE syndrome have been reported, and it is cconsidered one of the most common neurocutaneous vascular disorders in childhood (3).

PHACE syndrome is observed in 2% to 3% of IH cases (3)

Approximately 90% of the hemangiomas in PHACE syndrome are located on the cephalic segment (3)

  • the face is the most commonly affected site, but lesions can develop on the scalp and postauricular and cervical regions
  • large and segmental IHs on the occipital, upper thoracic, trunk, and proximal upper limb regions have also been described in PHACE syndrome

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.